Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

C Bolling,T. Graefe,C. Lübbing,F. Jankevicius,S. Uktveris,A. Cesas,W.-H. Meyer-Moldenhauer,H. Starkmann,M Weigel,K. Burk,A.-R. Hanauske

Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

2006

C Bolling
T. Graefe
C. Lübbing
F. Jankevicius
S. Uktveris
A. Cesas
W.-H. Meyer-Moldenhauer
H. Starkmann
M Weigel
K. Burk
A.-R. Hanauske

Purpose: To assess the efficacy, tolerability and safety of MTX-HSA (methotrexate (MTX) covalently linked to human serum albumin (HSA)) combined with cisplatin as first line therapy for advanced bladder cancer.

Keywords:

Cisplatin
Phases of clinical research
Metastatic Transitional Cell Carcinoma
Methotrexate
Bladder cancer
Transitional cell carcinoma
Human serum albumin
Oncology
Tolerability
Internal medicine
Medicine
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations